Novartis discontinues late-stage remibrutinib trial in myasthenia gravis

Novartis announced the discontinuation of a late-stage clinical trial for its drug remibrutinib in the treatment of generalized myasthenia gravis.

Detected & updated continuously · Source: Nebula